Seattle Children's opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins

(Seattle Children's) Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the US for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news